Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

This study has been terminated.

( Withdrawal of marketing autorization of efalizumab by the EMEA. )

Study NCT00608777 Information provided by Derm Research, PLLC

First Received: January 23, 2008 Last Updated: March 9, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been terminated.
Study Completion Date:	February 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)